@article{7bcdc65eaa38462fba0629ab50bf0c21,
title = "Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials",
abstract = "In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.",
keywords = "HCV, OST, PWID, Sofosbuvir, Velpatasvir",
author = "Jason Grebely and Dore, {Gregory J.} and Stefan Zeuzem and Aspinall, {Richard J.} and Raymond Fox and Lingling Han and John McNally and Anu Osinusi and Brainard, {Diana M.} and Subramanian, {G. Mani} and Macky Natha and Foster, {Graham R.} and Alessandra Mangia and Mark Sulkowski and Feld, {Jordan J.}",
note = "Funding Information: The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian government. J. G. is supported by a National Health and Medical Research Council Career Development Fellowship. G. J. D. is supported through National Health and Medical Research Council of Australia (NHMRC) practitioner fellowships. M. S. is supported in part by the National Institutes of Health, National Institute on Drug Abuse (K24 DA034621-01). The phase 3 ASTRAL trials were funded by Gilead Sciences. J. G. is a consultant/advisor and has received research grants from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck/MSD. G. J. D. is a consultant/advisor and has received research grants from AbbVie, Abbot Diagnostics, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Merck, Janssen, and Roche. S. Z. is a consultant/advisor for AbbVie, BMS, Gilead, Janssen, and Merck/MSD. R. J. A. has received speaker honoraria from Gilead Sciences. R. F. is a consultant/advisor for Gilead, Merck, BMS, and AbbVie. G. R. F. reports speaker and consultancy fees from Roche, Merck, Gilead Sciences, Novartis, AbbVie, Janssen, Bristol-Myers Squibb, Boehringer Ingelheim, Idenix, and Achillion. A. M. is a consultant/advisor for BMS, Gilead, Janssen, Merck/MSD, and Roche. M. S. is a consultant/advisor for AbbVie, Cocrystal, Gilead, Janssen, Merck, and Trek; serves as the principal investigator for research grants to the Johns Hopkins University from AbbVie, BMS, Gilead, Janssen, and Merck; and has received payment for the development of educational programs for Clinical Care Option, ViralEd, and DKB. J. J. F. is a consultant/advisor and has received research grants from AbbVie, Bristol Myers Squibb, Gilead, Merck, Janssen, Regulus, Santaris, and Theravance. L. H., J. M., A. O., D. M. B., M. S., and M. N. are employees of Gilead Sciences. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Publisher Copyright: {\textcopyright} The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.",
year = "2016",
month = dec,
day = "1",
doi = "10.1093/cid/ciw579",
language = "English (US)",
volume = "63",
pages = "1479--1481",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "11",
}